Certificate published for every lotSame-day dispatch before 1pm, Monday to FridayFree Royal Mail Tracked 48 over £100
ALTAResearch peptides
Coming soonSemaglutide Pen 40 mg: ALTA box, pre-filled pen and needles
FormatPre-filled pen
AreaWeight & Metabolic
StatusComing soon
Weight & Metabolic · Pre-filled penComing soon

Semaglutide Pen 40 mg: semaglutide peptide pen for research

Pre-filled pen: 40 mg semaglutide, GLP-1 receptor agonist

Lot certificate published at release

A sealed pre-filled pen holding 40 mg of semaglutide, the 31-amino-acid GLP-1 receptor agonist peptide. Arriving soon in UK stock; register to hear the price and release date first.

Coming soonPrice to be announced
Email me when Semaglutide Pen is available, plus new lots and offers. Unsubscribe any time. Privacy
  • Price and release date posted here first
  • Lot certificate published before it goes on sale
  • Royal Mail Tracked 48, free over £100, plain packaging
In stock now: retatrutide penThe triple agonist from the same GLP-1 family, with five phase 3 trials →
§ 01

Specification

Data sheet · provisional
Compound
Semaglutide
Class
GLP-1 receptor agonist
Structure
31-amino-acid GLP-1 analogue with a C18 fatty diacid side chain
Molecular formula
C187H291N45O59
Molecular weight
4,113.6 g/mol
CAS number
910463-68-2
Contents
40 mg semaglutide per pen
Format
Sealed pre-filled pen; manufacturer and lot certificate confirmed at release
Storage
2 to 8 °C, protected from light. Do not freeze.
Price
Coming soon
§ 02

About Semaglutide Pen

What semaglutide is

Semaglutide is a synthetic peptide, 31 amino acids long, that copies the gut hormone GLP-1. Natural GLP-1 is released after a meal, slows the stomach, reduces appetite and helps the pancreas release insulin when blood sugar is high, but it is broken down within about two minutes. The semaglutide peptide has two changes that protect it: one swapped amino acid that blocks the enzyme DPP-4, and a fatty-acid side chain that binds albumin in the blood. Together they stretch its half-life to about a week.

It was developed by Novo Nordisk and is the active ingredient in the licensed medicines Ozempic, Wegovy and Rybelsus. Our GLP-1 receptor agonists explainer tells the story from the first GLP-1 drugs to today.

What the trials reported

In STEP 1, a 68-week trial in 1,961 adults with obesity published in the New England Journal of Medicine in 2021, average body-weight loss was 14.9% in the semaglutide 2.4 mg arm against 2.4% on placebo. In the SELECT trial of 17,604 adults with cardiovascular disease, published in 2023, semaglutide reduced major cardiovascular events by 20%. The most common side effects reported in the trials were nausea, diarrhoea, vomiting and constipation.

Semaglutide vs tirzepatide vs retatrutide

Semaglutide acts on one receptor (GLP-1), tirzepatide on two (GIP and GLP-1) and retatrutide on three (GIP, GLP-1 and glucagon). In SURMOUNT-5, a direct 72-week comparison published in 2025, semaglutide produced 13.7% average weight loss against 20.2% for tirzepatide. Retatrutide reported 28.3% at 80 weeks in its own TRIUMPH-1 trial. Our retatrutide vs tirzepatide vs semaglutide comparison sets the trials side by side, and our article on muscle loss on GLP-1 peptides covers the body-composition data. The tirzepatide pen is also coming soon, and the retatrutide pen and retatrutide vials are in stock now.

The 40 mg pen

The semaglutide pen is a sealed, pre-filled pen containing 40 mg of semaglutide in solution, filled by the manufacturer, not by ALTA PEPTIDES. A pen arrives ready-made, where a semaglutide vial is a dry powder that a laboratory reconstitutes itself. Our pen vs vial guide explains the trade-offs, which are the same for every peptide in this class. The certificate of analysis for the semaglutide in each lot will be published on this page before the pen goes on sale.

UK status

Semaglutide is the active ingredient in Ozempic, Wegovy and Rybelsus, prescription-only medicines licensed in the UK. This pen is not Ozempic or Wegovy, is not made or endorsed by Novo Nordisk, and is not a medicine. It is research-grade semaglutide supplied for laboratory research only, not for human use. Anyone seeking treatment should speak to a doctor or a registered pharmacy. Our guide to UK peptide law explains the difference between licensed medicines and research compounds.

Availability

The semaglutide 40 mg pen is arriving soon in UK stock. The price, release date and lot certificate will be posted here first. Register above to be told the day it is available.

Semaglutide peptide in licensed medicines, and what this research pen is not

Semaglutide is a long-acting analogue of the incretin hormone glucagon-like peptide-1. The UK prescribing information for Ozempic describes it as a GLP-1 receptor agonist that binds to and activates the GLP-1 receptor. It reports that semaglutide lowers blood glucose by stimulating insulin secretion and lowering glucagon secretion when glucose is high, with a minor delay in gastric emptying after a meal. Ozempic is licensed for the treatment of adults with insufficiently controlled type 2 diabetes, and Wegovy for weight management in adults, each as a weekly subcutaneous injection. Liraglutide (Saxenda) is another GLP-1 analogue in the same pharmacological class.

Those are prescription-only medicines, made by Novo Nordisk and supplied through a prescriber or a registered pharmacy. The pen listed on this page is a different thing. It is a research item that is not in stock, it is not Wegovy or Ozempic, and it is not a licensed medicine. As a supplier, ALTA lists it for laboratory research use only, not for human consumption, and gives no guidance on human use. Our GLP-1 receptor agonists explainer covers the metabolic research behind the class.

For laboratory research use only. Not for human or veterinary use, not for diagnostic or therapeutic use, not a medicine or a supplement. Sold to researchers aged 18 and over. Nothing on this page is a recommendation for any use of this compound.
§ 03

Questions

When will the semaglutide pen be available?
It is arriving soon in UK stock. The price, release date and the lot certificate will be posted on this page first. Register your email above to be told the day it is available.
How much will the semaglutide 40 mg pen cost?
The price is not set yet. It will be published here before release, with the price per milligram so it can be compared with other pens and vials.
What is semaglutide?
Semaglutide is a 31-amino-acid synthetic peptide that copies the gut hormone GLP-1. It was developed by Novo Nordisk and is the active ingredient in the licensed medicines Ozempic, Wegovy and Rybelsus.
Is this Ozempic or Wegovy?
No. Ozempic and Wegovy are Novo Nordisk's licensed, prescription-only medicines. This is a research-grade semaglutide pen from a third-party manufacturer, supplied for laboratory research only and not for human use.
Is semaglutide a peptide?
Yes. Semaglutide is a peptide of 31 amino acids, 94% identical to human GLP-1, with a C18 fatty diacid attached so that it lasts about a week in the blood.
Semaglutide vs tirzepatide: which did better in trials?
In SURMOUNT-5, a direct 72-week comparison published in 2025, tirzepatide produced 20.2% average weight loss against 13.7% for semaglutide. Semaglutide acts on the GLP-1 receptor alone; tirzepatide also acts on GIP.
Semaglutide vs retatrutide: what is the difference?
Semaglutide acts on one receptor, GLP-1. Retatrutide acts on three: GLP-1, GIP and glucagon. In separate trials semaglutide produced 14.9% average weight loss at 68 weeks and retatrutide 28.3% at 80 weeks.
Can you buy semaglutide in the UK?
As a medicine, semaglutide (Ozempic, Wegovy) is prescription-only and comes from a doctor or registered pharmacy. ALTA PEPTIDES will supply this pen as a research compound for laboratory use only, to researchers aged 18 and over.
What is a semaglutide research pen?
A semaglutide research pen is a sealed, pre-filled pen sold as a laboratory research compound rather than as a medicine. This semaglutide peptide pen will hold 40 mg of semaglutide in solution, filled by a third-party manufacturer, with a certificate of analysis published for each lot. It is not Ozempic or Wegovy and it is not for human use.
Do semaglutide peptides come as a pen or a vial?
Both formats exist. Semaglutide peptides for laboratory research are supplied either as a sealed pre-filled pen, which holds the peptide in solution, or as a vial of dry powder that a laboratory reconstitutes itself. This listing is the 40 mg pen; as a semaglutide research peptide it is for laboratory use only.
How does semaglutide work?
According to the UK prescribing information for Ozempic, semaglutide activates the GLP-1 receptor, stimulates insulin secretion and lowers glucagon secretion when blood glucose is high, and causes a minor delay in gastric emptying after a meal. The same document reports lower energy intake and reduced appetite.
Is semaglutide licensed for type 2 diabetes or for weight management?
Both, as different medicines. Ozempic is indicated for adults with type 2 diabetes that is insufficiently controlled, as an adjunct to diet and exercise. Wegovy is indicated for weight management in adults, alongside a reduced-calorie diet and increased physical activity. Both are prescription-only medicines.
Is the semaglutide pen on this page a licensed medicine?
No. It is a research item that is not in stock. It is not Wegovy or Ozempic, it is not made or endorsed by Novo Nordisk, and it is not a licensed medicine.
§ 04

In stock now

See all →
Retatrutide Pen pre-filled penNewNo. 014
Weight & MetabolicPen

Retatrutide Pen

Synedica pre-filled pen: 40 mg retatrutide, with needles

Size
40 mg pen
HPLC
99.752%
Lot
07022601
£139.99£3.50/mg